Galis Z S, Kranzhöfer R, Fenton J W, Libby P
Emory University School of Medicine, Cardiology Division, Atlanta, GA 30322, USA.
Arterioscler Thromb Vasc Biol. 1997 Mar;17(3):483-9. doi: 10.1161/01.atv.17.3.483.
Thrombin generated at sites of vascular injury not only participates in the coagulation cascade but can signal other events related to development and complication of atherosclerotic plaques. We investigated here a novel non-thrombotic action of thrombin: the possibility that this protease influences the expression or activation of matrix metalloproteinases (MMPs) produced by vascular smooth muscle cells (SMCs). Matrix-degrading proteinases likely contribute to several aspects of vascular lesion development. Vascular SMCs constitutively elaborate the zymogen form of gelatinase A (MMP-2), found in cell supernatants complexed with its inhibitor, the tissue inhibitor of metalloproteinases (TIMP)-2. When activated, MMP-2 digests collagens and elastin and may thus promote cell migration and vascular remodeling. Analysis of culture supernatants harvested from either human or rabbit vascular SMCs by gelatin zymography revealed that compared with supernatants of unstimulated SMCs, media conditioned by thrombin-stimulated cells contained increased amounts of proteolytically processed MMP-2, suggesting activation of this MMP. Further experiments tested whether thrombin directly activates MMP-2. In cell-free experiments, when added to medium harvested from unstimulated SMCs, alpha-thrombin increased in a dose- and time-dependent manner the amount of proteolytically processed MMP-2, as shown by zymography and by Western blotting with specific antibodies. Thrombin cleaved pro-MMP-2 within 4 hours, even when the gelatinase was bound with its inhibitor, TIMP-2. Thrombin treatment rendered culture media of unstimulated SMCs able to degrade collagen type IV, consistent with generation of active MMP-2. Addition of inhibitors of either thrombin or MMPs decreased this type IV collagenolytic activity, but thrombin in the absence of SMC-conditioned medium containing pro-MMP-2 exhibited only minimal collagenolysis. Our results suggest that at sites of vascular injury, thrombin may activate locally produced MMP-2 and thereby facilitate cell migration and proliferation. In the case of complicated atherosclerotic plaques, episodes of intraplaque hemorrhage or plaque disruption with thrombosis may promote plaque instability by increasing local matrix-degrading activity.
在血管损伤部位产生的凝血酶不仅参与凝血级联反应,还能引发与动脉粥样硬化斑块发展和并发症相关的其他事件。我们在此研究了凝血酶一种新的非血栓形成作用:这种蛋白酶影响血管平滑肌细胞(SMC)产生的基质金属蛋白酶(MMP)表达或激活的可能性。基质降解蛋白酶可能在血管病变发展的多个方面起作用。血管SMC持续分泌明胶酶A(MMP-2)的酶原形式,在细胞上清液中与其抑制剂金属蛋白酶组织抑制剂(TIMP)-2结合。激活后,MMP-2可消化胶原蛋白和弹性蛋白,从而可能促进细胞迁移和血管重塑。通过明胶酶谱分析从人或兔血管SMC收获的培养上清液,发现与未刺激SMC的上清液相比,凝血酶刺激细胞条件培养基中蛋白水解处理的MMP-2含量增加,提示该MMP被激活。进一步实验检测凝血酶是否直接激活MMP-2。在无细胞实验中,当将α-凝血酶添加到未刺激SMC收获的培养基中时,酶谱分析和用特异性抗体进行的蛋白质印迹显示,其以剂量和时间依赖性方式增加蛋白水解处理的MMP-2的量。即使明胶酶与其抑制剂TIMP-2结合,凝血酶也能在4小时内切割前MMP-2。凝血酶处理使未刺激SMC的培养基能够降解IV型胶原,这与活性MMP-2的产生一致。添加凝血酶或MMP抑制剂可降低这种IV型胶原溶解活性,但在不含前MMP-2的SMC条件培养基的情况下,凝血酶仅表现出最小程度的胶原溶解。我们的结果表明,在血管损伤部位,凝血酶可能局部激活产生的MMP-2,从而促进细胞迁移和增殖。在复杂动脉粥样硬化斑块的情况下,斑块内出血或斑块破裂伴血栓形成事件可能通过增加局部基质降解活性促进斑块不稳定。